News

Health Rounds: Roche's Tecentriq reduces recurrence, deaths for certain colon cancer patients
Adding Roche's immunotherapy drug Tecentriq to chemotherapy after surgery in certain patients whose colon cancer had spread ...
Devdiscourse35m
Breakthroughs and Controversies: New Findings in Cancer and Heart Treatment
Recent trials unveil significant advances in cancer treatment with immunotherapy drug Tecentriq, showing a 50% reduction in ...
Combo therapy may cut stage 3 colon cancer recurrence, death risk by 50%
Adding immunotherapy to chemotherapy after surgery for stage 3 colon cancer may help decrease recurrence and death rate by 50 ...
Pharmabiz6h
Vividion Therapeutics secures worldwide rights to develop & commercialize clinical-stage WRN covalent inhibitor, VVD-214
Vividion Therapeutics secures worldwide rights to develop & commercialize clinical-stage WRN covalent inhibitor, VVD-214: San Diego, California Friday, June 6, 2025, 11:00 Hrs [IS ...
Pharmabiz8h
China NMPA accepts Hutchmed & Innovent’s NDA for fruquintinib in combo with sintilimab to treat advanced renal cell carcinoma
China NMPA accepts Hutchmed & Innovent’s NDA for fruquintinib in combo with sintilimab to treat advanced renal cell carcinoma: Hong Kong, Shanghai Friday, June 6, 2025, 09:00 Hr ...